A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro

L-Asparaginases (ASNases) have been used as first line drugs for paediatric Acute Lymphoblastic Leukaemia (ALL) treatment for more than 40 years. Both the Escherichia coli (EcAII) and Erwinia chrysanthemi (ErAII) type II ASNases currently used in the clinics are characterized by high in vivo instabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Maggi, Maristella, Mittelman, Steven D., Parmentier, Jean Hugues, Colombo, Giorgio, Meli, Massimiliano, Whitmire, Jeannette Marie, Merrell, D. Scott, Whitelegge, Julian, Scotti, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670125/
https://www.ncbi.nlm.nih.gov/pubmed/29101342
http://dx.doi.org/10.1038/s41598-017-15075-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670125/
https://www.ncbi.nlm.nih.gov/pubmed/29101342
http://dx.doi.org/10.1038/s41598-017-15075-4

Ejemplares similares